CN114746414B - 氮杂-喹啉化合物及其用途 - Google Patents
氮杂-喹啉化合物及其用途 Download PDFInfo
- Publication number
- CN114746414B CN114746414B CN202080067448.9A CN202080067448A CN114746414B CN 114746414 B CN114746414 B CN 114746414B CN 202080067448 A CN202080067448 A CN 202080067448A CN 114746414 B CN114746414 B CN 114746414B
- Authority
- CN
- China
- Prior art keywords
- amino
- methyl
- cyclohexyl
- trans
- naphthyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019108296 | 2019-09-26 | ||
| CNPCT/CN2019/108296 | 2019-09-26 | ||
| PCT/CN2020/117487 WO2021057853A1 (en) | 2019-09-26 | 2020-09-24 | Aza-quinoline compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114746414A CN114746414A (zh) | 2022-07-12 |
| CN114746414B true CN114746414B (zh) | 2024-10-18 |
Family
ID=75166744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080067448.9A Active CN114746414B (zh) | 2019-09-26 | 2020-09-24 | 氮杂-喹啉化合物及其用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12544374B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4034535B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7763753B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102889562B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114746414B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020355837B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150284A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4034535T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3067468T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291499B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021057853A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4034535T3 (da) | 2019-09-26 | 2026-04-07 | Novartis Ag | Aza-quinolinforbindelser og anvendelser deraf |
| AR123185A1 (es) * | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
| AR128015A1 (es) * | 2021-12-16 | 2024-03-20 | Transthera Sciences Nanjing Inc | Inhibidor de cdk9 y uso del mismo |
| CN117384153A (zh) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | 一类甲基转移酶抑制剂及其用途 |
| CN118515653B (zh) * | 2024-07-23 | 2024-12-10 | 西湖制药(杭州)有限公司 | 一种ezh2特异性抑制剂及其制备方法和用途 |
| CN118598873B (zh) * | 2024-08-07 | 2024-11-19 | 艾斯拓康生物医药(天津)有限公司 | 一种手性的氮杂-喹啉类化合物的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108637A (zh) * | 2014-12-23 | 2017-08-29 | 诺华股份有限公司 | 三唑并嘧啶化合物及其用途 |
| CN107849032A (zh) * | 2015-06-30 | 2018-03-27 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2抑制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Mek阻害剤による関節炎の治療 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2014155301A1 (en) | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
| JP2019524872A (ja) | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
| US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| MX2019004950A (es) | 2016-10-28 | 2019-09-26 | Icahn School Med Mount Sinai | Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2. |
| DK4034535T3 (da) | 2019-09-26 | 2026-04-07 | Novartis Ag | Aza-quinolinforbindelser og anvendelser deraf |
-
2020
- 2020-09-24 DK DK20868772.3T patent/DK4034535T3/da active
- 2020-09-24 JP JP2022519331A patent/JP7763753B2/ja active Active
- 2020-09-24 IL IL291499A patent/IL291499B2/en unknown
- 2020-09-24 US US17/632,990 patent/US12544374B2/en active Active
- 2020-09-24 AU AU2020355837A patent/AU2020355837B2/en active Active
- 2020-09-24 EP EP20868772.3A patent/EP4034535B1/en active Active
- 2020-09-24 WO PCT/CN2020/117487 patent/WO2021057853A1/en not_active Ceased
- 2020-09-24 ES ES20868772T patent/ES3067468T3/es active Active
- 2020-09-24 CA CA3150284A patent/CA3150284A1/en active Pending
- 2020-09-24 KR KR1020227011716A patent/KR102889562B1/ko active Active
- 2020-09-24 CN CN202080067448.9A patent/CN114746414B/zh active Active
-
2025
- 2025-11-21 US US19/396,743 patent/US20260076968A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108637A (zh) * | 2014-12-23 | 2017-08-29 | 诺华股份有限公司 | 三唑并嘧啶化合物及其用途 |
| CN107849032A (zh) * | 2015-06-30 | 2018-03-27 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7763753B2 (ja) | 2025-11-04 |
| EP4034535A1 (en) | 2022-08-03 |
| CN114746414A (zh) | 2022-07-12 |
| US20260076968A1 (en) | 2026-03-19 |
| KR20220070229A (ko) | 2022-05-30 |
| US12544374B2 (en) | 2026-02-10 |
| AU2020355837B2 (en) | 2025-10-02 |
| IL291499B1 (en) | 2025-04-01 |
| WO2021057853A1 (en) | 2021-04-01 |
| KR102889562B1 (ko) | 2025-11-24 |
| AU2020355837A1 (en) | 2022-02-24 |
| IL291499B2 (en) | 2025-08-01 |
| DK4034535T3 (da) | 2026-04-07 |
| CA3150284A1 (en) | 2021-04-01 |
| US20220280509A1 (en) | 2022-09-08 |
| ES3067468T3 (en) | 2026-05-22 |
| JP2022550353A (ja) | 2022-12-01 |
| EP4034535B1 (en) | 2026-03-04 |
| EP4034535A4 (en) | 2023-11-22 |
| IL291499A (en) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11897869B2 (en) | JAK1 selective inhibitors | |
| JP7763753B2 (ja) | アザキノリン化合物およびその使用 | |
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| CN109906224B (zh) | 三唑吡啶化合物及其应用 | |
| JP2019524872A (ja) | 癌の治療に有用なイミダゾピリミジン化合物 | |
| CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
| CN114555589B (zh) | 用于抑制ezh2的化合物和组合物 | |
| JP2022539208A (ja) | チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用 | |
| CN117024363A (zh) | 环烯烃取代的杂芳环类化合物及其用途 | |
| CN115181092B (zh) | 吡嗪化合物和其用途 | |
| HK40077297A (en) | Aza-quinoline compounds and uses thereof | |
| HK40077297B (en) | Aza-quinoline compounds and uses thereof | |
| HK40117897A (en) | Compounds and compositions for inhibiting ezh2 | |
| HK40080941B (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases | |
| HK40080941A (en) | Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases | |
| HK40098388A (en) | Jak1 selective inhibitors | |
| HK40130960A (en) | Tricyclic compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40077297 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |